Podcasts about Amgen

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment. In the realm of weight management and metabolic disorders, significant advancements are underway. Roche and Zealand Pharma have moved Petrelintide, an amylin analog, into a Phase 3 clinical trial after a promising Phase 2 showing a nearly 10% weight loss in participants. This development highlights an increasing focus on protein-based therapies for metabolic conditions, offering new hope for tackling obesity—a major global health challenge. Similarly, Eli Lilly's Retatrutide has made headlines with its Phase 3 trial results, demonstrating a remarkable 25% body weight reduction in obese patients with type 2 diabetes. This triple agonist targets multiple receptors, marking a novel approach in metabolic therapeutics that could transform obesity and diabetes management by targeting key pathways regulating energy balance and glucose levels. In oncology, Pierre Fabre and Atara Biotherapeutics have resubmitted their Biologics License Application for Ebvallo (tabelecleucel) to the FDA. This follows successful Phase 3 trials targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a severe complication post-transplantation. If approved, tabelecleucel could provide a critical allogeneic T-cell therapy option for these patients, underscoring the evolution of cell-based therapies in cancer treatment. Regulatory news is also making waves with Segetis Therapeutics receiving FDA approval for Emcitate (tiratricol), designed to treat monocarboxylate transporter 8 deficiency. This approval is particularly significant as it marks the first U.S. treatment for this rare pediatric thyroid hormone disorder, showcasing the industry's dedication to addressing rare diseases' unmet needs. Meanwhile, artificial intelligence continues to reshape drug discovery and development processes. Collaborations such as GSK's with Wave Life Sciences on hepatic siRNA programs and Novartis Biomedical Research's partnership with CAS aim to enhance drug discovery workflows through advanced data analytics and machine learning models. In clinical trial news, Highlight Therapeutics reported successful Phase 2 results for BO-112 in high-risk head and neck basal cell carcinoma. The immunotherapy showed efficacy as an intralesional therapy, providing new hope for patients at high risk of cancer recurrence or progression. Furthermore, Amgen's Daxdilimab demonstrated positive outcomes in a Phase 2 trial for discoid lupus erythematosus by significantly reducing disease severity, highlighting interest in targeted therapies for autoimmune conditions. Connect Biopharma's Rademikibart has shown promise in reducing exacerbations of chronic obstructive pulmonary disease during its Phase 2 trial. As an IL-4/IL-13 inhibitor, it stands as a potential competitor to existing treatments like Dupixent, potentially reshaping therapeutic strategies in respiratory diseases. These advancements reflect broader trends within the pharmaceutical industry towards personalized medicine, innovative drug mechanisms, and strategic partnerships leveraging AI and advanced analytics. As these therapies progress through clinical trials and regulatory pathways, they hold promise for enhancing patient care and expanding treatment options across various disease areas. In related regulatory developments, the European Commission has revoked marketing authorization for Hansoh Pharma's Aumseqa following a legal challenge by AstraZeneca. This decision underscores the competitive nature of oncology and highlights the importance of patent disputes and regulatory compliance in maintaining market presence. On the corporate strategy front, PhRMA has appointed former House Majority Leader Eric Cantor as its CEO. This move indicates PhRMA's focus on navigating complex regulatory environments crucial for shaping healthcare policies impacting drug development and pricing. The White House is also taking steps to address global supply chain vulnerabilities by boosting domestic production of essential medicines—a strategy aimed at enhancing national security while ensuring a steady supply of critical drugs. In industry funding news, NorthStar Medical Technologies secured $185 million to advance radiopharmaceutical isotope production. With commercial-scale manufacturing of Actinium-225 completed earlier this year, NorthStar is set to significantly increase capacity by year-end—reflecting growing demand within precision medicine. In space-based innovations, Varda Space Industries raised $251 million to fuel pioneering drug manufacturing using reusable rockets in Earth's low orbit—potentially revolutionizing drug production by utilizing microgravity environments. Finally, recent developments highlight challenges within the industry as well. Companies like Novo Nordisk and BioMarin face layoffs amid evolving market demands. Meanwhile, Enanta Pharmaceuticals downsizes amid forthcoming antiviral readouts—a reflection of broader strategic pivots required to remain competitive. These developments underscore an era where scientific breakthroughs are rapidly transforming drug development paradigms. As companies navigate intellectual property challenges and strategic collaborations continue to drive innovation aimed at addressing diverse unmet medical needs across therapeutic areas, stakeholders are likely to witness continued growth and transformation in drug development and delivery paradigms worldwide. Thank you for joining us on Pharma Daily—your go-to source for insights into the ever-evolving pharmaceutical and biotech industries. Stay tuned for more updates as we continue to explore groundbreaking advancements shaping the future of medicine.Support the show

Colleen Walson-Billin was told she was not eligible to progress in Quality without a science degree, and went on to lead a full GxP Quality function at a biologics startup.Colleen Walson-Billin on building a Quality career without a science degree.In today's episode I was joined by Colleen Walson-Billin, Vice President & Head of GxP Quality & Compliance at Jade Biosciences. I wanted to speak to Colleen because her route into Quality started with a business degree and a role as administrative assistant to a director of Quality at Amgen. From there she moved through QA, corporate and international Quality, served twice as chief of staff to the head of Quality, and now leads Quality across GMP, GCP, GLP and pharmacovigilance.We talk about:Starting in Quality as an administrative assistant, and telling her first boss up front that the role was her foot in the doorBeing told she was not eligible to progress without a science degree, and building her technical knowledge on the jobServing twice as chief of staff to the head of Quality, and what she learned at the table with the leadership teamLeaving Amgen for smaller companies, and picking up GCP, GLP and pharmacovigilance for the first timeLeading executive and senior directors, stepping back from being the doer, and positioning Quality as a partner from the startThank you Colleen for sharing your journey.Timestamps:(00:00) Introduction(00:46) "My foot in the door": business degree to admin assistant(05:02) "You're just not even eligible"(08:51) The advice that made the degree stop mattering(12:34) A career with no plan, built by putting her hand up(19:14) Leaving Amgen for a smaller company(22:01) Employee number 24, and "enough to be dangerous" across GxP(25:14) Why the degree becomes almost irrelevant at 20 years(29:50) Roadblocks, naysayers and the police: old school Quality(35:06) Selling Quality to a room of college students(40:03) Inspired by what she did not want to become

On this week's episode, Sam Fazeli, Yaron Werber, Brian Skorney, and Matt Gline open with the IPO market, noting record average raise sizes even as XBI softens. The group turns to policy, unpacking newly FOIA-disclosed details of Pfizer's MFN agreement, including a revenue-share provision tied to price increases abroad. The co-hosts call the equalization concept constructive but warn cash-strapped European governments may ration access rather than pay more. They also discuss FDA commissioner nominee Heidi Overton's confirmation hearing, where innovation-forward opening remarks were read as a positive signal despite lingering questions about her MAHA alignment. In data news, Compass Therapeutics pushed ahead with bispecific tovecimig despite FDA's request for an overall-survival trial, while Vertex's inaxaplin data broadened the case for efficacy beyond FSGS kidney patients. Amgen's dazodalibep for Sjögren's hit its primary endpoint in a Phase 3 trial, and Viking's VK2735 posted strong Phase 1 maintenance-dosing data in obesity. Celdex's barzolvolimab cleared both primary and secondary endpoints in urticaria, and Alkermes' ALKS 7290 succeeded in ADHD, adding to orexin-agonist momentum. The episode closed with Moderna's melanoma vaccine data tapped for ESMO's top plenary slot and Lexeo's $8.3 billion acquisition of Mantle Therapeutics. *This episode aired on September 25, 2026.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is pulsating with advancements, strategic collaborations, regulatory approvals, and promising clinical trial results that are reshaping the landscape of healthcare and drug development. A notable collaboration making waves is between Boehringer Ingelheim and Envisagenics, a partnership valued at $1 billion. This multi-year agreement harnesses artificial intelligence in RNA splicing through the SpliceCore platform, particularly targeting oncology. This move underscores a growing trend to integrate AI and machine learning into drug discovery processes, emphasizing precise genetic interventions that could transform cancer therapies by accelerating and refining development processes. Boehringer Ingelheim's collaboration with Envisagenics marks a significant investment into oncology research using AI to identify novel tumor-specific targets. In regulatory news, Johnson & Johnson's Caplyta has achieved its primary endpoint in a Phase 3 trial focused on manic episodes associated with Bipolar I disorder. As an atypical antipsychotic, Caplyta offers a promising therapeutic option for managing this complex condition, potentially expanding treatment arsenals in neurological disorders. Further, AbbVie's Rinvoq has been approved by the European Commission for pediatric polyarticular juvenile idiopathic arthritis, marking an expansion of JAK inhibitors in treating autoimmune diseases. This approval provides much-needed hope for pediatric patients grappling with debilitating conditions. Meanwhile, Menarini Group and NewAmsterdam Pharma's cardiovascular drugs Ubeslo and Evlarco have also secured European Commission approval. These CETP inhibitors address hypercholesterolemia, offering innovative approaches in managing cholesterol levels—a key factor in cardiovascular disease risk. The business landscape is robust with key partnerships emphasizing AI-driven drug discovery. AbbVie has teamed up with Iambic Therapeutics to explore AI applications across immunology, neuroscience, and oncology. Meanwhile, Novartis has entered into a licensing deal with BoomRay Pharmaceuticals for preclinical radioligand therapy, highlighting an ongoing interest in breakthrough cancer treatments. Geographical dynamics are shifting as forecasts predict increased Western licensing deals for Chinese radioligand therapies by 2027. This trend highlights global biotech ecosystems' interconnectivity and cross-border innovation potential. In clinical trials, Otsuka and Ionis Pharmaceuticals' ulefnersen achieved its Phase 3 primary endpoint for FUS-ALS, marking progress toward FDA discussions for RNA-targeted therapies in ALS treatment. Vertex's Inaxaplin has shown positive Phase 2b results for APOL1-mediated kidney disease. Amgen's Dazodalibep met its Phase 3 endpoint by easing Sjogren's disease severity through CD40 ligand targeting. Amgen has made headway with its investigational drug for Sjogren's disease. Its Phase 3 trial success is crucial for Amgen's Horizon Therapeutics-acquired pipeline, offering new hope for patients with challenging autoimmune conditions. IPO activities are also buzzing. Iambic Therapeutics plans to advance its AI-driven HER2 inhibitor IAM1363 through an IPO, spotlighting AI's burgeoning role in oncology drug development and its potential to revolutionize personalized cancer treatment strategies. On the regulatory front, the FDA is actively pushing forward with approvals for key products. Merck's Winrevair and Nuvation's Ibtrozi are leading this wave of regulatory activity that could shift market dynamics significantly. In diabetes treatment, Roche has shown promising results with its dual GLP-1/GIP receptor agonist in a Phase 2 trial. Meeting primary endpoints presents this drug candidate as a potential best-in-disease therapy for type 2 diabetes patients who are overweight or obese. Eli Lilly's early-stage data supports its GLP-1/GIP candidate's potential beyond metabolic diseases, offering revolutionary treatment paradigms for psychiatric disorders. Challenges persist despite these scientific achievements. A survey highlights that one-third of UK women feel their migraine pain isn't taken seriously due to gender biases, emphasizing the need for more empathetic healthcare practices. Strategic acquisitions continue to shape industry dynamics. Lexeo Therapeutics' acquisition of Friedreich ataxia assets underscores commitment to rare genetic disorders. Novo Nordisk is undergoing strategic workforce reductions to bolster R&D efforts while aiming to increase oral Wegovy production capacity by 2030—a strategic focus on scaling production capabilities. These developments underscore the importance of leveraging innovative technologies and strategic collaborations to address complex health challenges. The integration of AI, expansion of manufacturing capacities, and successful clinical outcomes are pivotal in advancing patient care and optimizing drug development pathways. These strides promise transformative impacts on global health outcomes in the coming years.Support the show

Mice on the space shuttle helped fast-track a medicine that strengthens bones.

This episode covers:  The role of AI in heart failure and prevention AI advances in interventional cardiology Training cardiologists of the future Host: Fielder Camm Guests: Benjamin Meder, Pim van der Harst, Jozine ter Maaten and Mark Westwood Want to watch that episode? Go to: https://esc365.escardio.org/event/2554 Disclaimer: ESC TV Today is supported by Novartis and Novo Nordisk through independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Dan Atar, Yasmina Bououdina, Fielder Camm, Nicolle Kraenkel, Jozine Ter Maaten, Pim Van der Harst and Mark Westwood have declared to have no potential conflicts of interest to report. Carlos Aguiar has adeclared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Benjamin Meder has declared to have potential conflicts of interest to report: Alexion, Alynlam, Amgen, Apple Inc., AstraZeneca, Bayer AG, BNK, Biontech, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Daiichi Sankyo, Deutsche Gesellschaft für Kardiologie, German Center for Cardiovascular Research, German Research Foundation, Hummingbird Diagnostics, Intellia, Johnson&Johnson, Klaus-Tschira Foundation, Informatics for Life, Leducq Foundation (CASTT), Novartis, Novo Nordisk, Pfizer, SA, Sixt, SMT, Space X, Zoll. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of dynamic and significant advancements across the industry, from strategic acquisitions to regulatory shifts and scientific innovations. In a bold move, Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million. This acquisition marks a strategic enhancement in Novartis's ability to deliver therapies directly to the brain, overcoming one of the most formidable challenges in treating neurological disorders. The potential to deliver antibodies and other therapeutic agents effectively across this barrier could lead to groundbreaking treatments for conditions like Alzheimer's disease and multiple sclerosis. This reflects a broader industry trend emphasizing improved drug delivery systems to boost treatment efficacy and patient outcomes. On the clinical advancement front, Sling Therapeutics has raised $123 million in a Series C funding round aimed at propelling its oral therapy for thyroid eye disease forward. Unlike traditional intravenous treatments, this oral therapy offers a more convenient option for patients, potentially improving adherence and quality of life. Meanwhile, Circle Pharma's $92.5 million Series E funding will support the development of its cyclin D1 inhibitor for breast cancer, showcasing innovation in oncology through the use of macrocycles that could provide more effective treatments with fewer side effects. Investments in AI and machine learning are also reshaping the landscape. Ginkgo Bioworks' collaboration with Novo Nordisk to construct an autonomous lab highlights the increasing role of automation in optimizing R&D productivity. Mithrl's $20 million Series A round further underscores this shift, focusing on developing an AI infrastructure platform for streamlined biopharma drug discovery processes. The regulatory environment continues to evolve with notable challenges. BioMarin has discontinued Phase 2 development of Voxzogo in Noonan syndrome due to shifting treatment landscapes, illustrating the dynamic nature of therapeutic development. Similarly, Novartis's halt on its TREM2 stabilizer after a Phase 2 failure in ALS research points to the complexities inherent in neurodegenerative disease studies. Maat Pharma faced a setback when its appeal was rejected regarding the EMA's negative opinion on its graft-versus-host disease candidate, Xervyteg. This instance highlights the stringent regulatory hurdles companies must navigate to bring novel therapies to market. Amid these developments, Gilead Sciences is strategically expanding into oncology and inflammation. Through several acquisitions, Gilead has diversified its portfolio significantly, emphasizing oncology as a central focus area given its high potential for addressing unmet needs and offering substantial returns on investment. Legend Biotech's appointment of Ingrid Zhang as CEO signals a strategic push into the competitive CAR-T cell therapy market. These therapies represent a revolutionary approach in personalized medicine for cancer treatment, with Legend positioning itself for growth and innovation. Bristol Myers Squibb and Ono Pharmaceutical are preparing to contest Amgen's efforts to launch a biosimilar for their oncology blockbuster Opdivo. This reflects broader competitive dynamics within the biologics market where biosimilars promise more cost-effective options, potentially reshaping market shares and pricing strategies. Manufacturing innovations are also at play with Ori Biotech securing a $120 million deal for an automated production platform in cell therapy manufacturing. Such advancements are crucial as cell therapies become more mainstream, necessitating scalable solutions that maintain quality while meeting demand. Operational expansions continue as Reckitt Benckiser allocates $600 million to upgrade its US operations, fostering innovation across health and hygiene product lines—an industry trend towards integrating R&D with manufacturing prowess to drive new product development. While challenges persist—illustrated by Novartis's multiple trial failures—the pharmaceutical and biotech sectors remain resilient with adaptive strategies focused on innovation. The ongoing advancements underscore not only scientific exploration but also strategic maneuvering amidst evolving regulatory landscapes. As AI reshapes talent acquisition strategies and technological advancements accelerate drug discovery processes, companies must navigate complex global health ecosystems poised for transformative growth. The focus remains on improving patient outcomes through cutting-edge science while balancing innovation with strategic realignment. Thank you for tuning into Pharma Daily—where we keep you abreast of pivotal industry shifts shaping the future of healthcare. Join us again tomorrow as we continue exploring these exciting developments impacting patient care worldwide.Support the show

Doonbeg is still reflecting on an extraordinary few days, with the Irish Open, Fáilte Fest and the visit of US President Donald Trump bringing huge attention — and large crowds — to the village.   But alongside the excitement, there was frustration among some locals and businesses over security barriers, traffic restrictions and the impression that Doonbeg was closed off.   Alan Morrissey was joined by the new Morrissey's Bar owner Eamonn Vaughan and local Fianna Fáil councillor and business owner Rita McInerney to discuss the experience and what lessons can be learned. Photo (c) Clare FM

On this week's episode, Tess Cameron, Brian Skorney, Paul Matteis, and Yaron Werber open with a look at markets, noting the XBI slipped just over 3% amid concerns about energy prices, inflation, and long-term U.S. fiscal health weighing on the rate-sensitive sector. The conversation then turns to policy, discussing new FDA leadership appointments including Karim Mikhail as CBER director, with hosts noting the industry's hope for a calmer, less chaotic regulatory tone. They highlight the FDA's apparent openness to psychedelics, pointing to stock reactions across the space. On the data front, Novartis's pelacarsen missed expectations reducing Lp(a) relative to rival programs from Amgen and Eli Lilly, while its DM1 program also fell short, shifting attention to Dyne Therapeutics' upcoming expansion cohort data. The hosts debate whether Novartis's setbacks make early-commercial, post-Phase 3 companies more attractive acquisition targets given looming loss-of-exclusivity pressure across large pharma. In other data news, Roivant's mosliciguat hit its Phase 2 primary endpoints in interstitial lung disease, with the company already advancing to Phase 3. The episode closes with Biohaven's epilepsy trial hold pending further metabolite data, and questions over whether the hold could affect its recent SK Pharma deal. This episode aired on September 11, 2026.

GLP-1 receptor agonists remain an important and rapidly changing area of pharmacy practice, with new therapies, expanding indications, and evolving safety considerations shaping patient care. This course reviews recent developments in GLP-1 therapy, including newly approved medications, emerging evidence related to nutrition and oral health, and practical considerations for patient counseling and long-term management. You will be better prepared to evaluate new evidence, counsel patients on the safe and effective use of GLP-1 therapies, and incorporate recent updates into clinical practice. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTJennifer D. Goldman, PharmD, CDCES, BC-ADM, FCCPProfessor of Pharmacy Practice/Director of Cardiometabolic ServicesMassachusetts College of Pharmacy-Boston, Well Life Medical  Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent developments in GLP-1 therapies, including newly approved medications.2. Explain pharmacist-relevant considerations for counseling, safety monitoring, and long-term management of patients receiving GLP-1 therapies.Jennifer Goldman is a member of the speakers bureau for Novo Nordisk, Amgen, Lilly, Xeris, CeQur, and Abbott Diabetes. All relevant financial relationships have been mitigated.  0.075 CEU/0.75 HrUAN: 0107-0000-26-323-H01-PInitial release date: 9/14/2026Expiration date: 9/14/2029Additional CPE details can be found here.

GLP-1 receptor agonists remain an important and rapidly changing area of pharmacy practice, with new therapies, expanding indications, and evolving safety considerations shaping patient care. This course reviews recent developments in GLP-1 therapy, including newly approved medications, emerging evidence related to nutrition and oral health, and practical considerations for patient counseling and long-term management. You will be better prepared to evaluate new evidence, counsel patients on the safe and effective use of GLP-1 therapies, and incorporate recent updates into clinical practice.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTJennifer D. Goldman, PharmD, CDCES, BC-ADM, FCCPProfessor of Pharmacy Practice/Director of Cardiometabolic ServicesMassachusetts College of Pharmacy-Boston, Well Life Medical GET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates-  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent developments in GLP-1 therapies, including newly approved medications.2. Explain pharmacist-relevant considerations for counseling, safety monitoring, and long-term management of patients receiving GLP-1 therapies.Jennifer Goldman is a member of the speakers bureau for Novo Nordisk, Amgen, Lilly, Xeris, CeQur, and Abbott Diabetes. All relevant financial relationships have been mitigated.0.075 CEU/0.75 HrUAN: 0107-0000-26-323-H01-PInitial release date: 9/14/2026Expiration date: 9/14/2029Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

We've been talking about the politics of Donald Trump's visit, but the stated reason for the President's presence is the Irish Open. So Paul caught-up on what's happening on the golf course with the man who knows it all: Greg Allen.See omnystudio.com/listener for privacy information.

Why did a failed Novartis drug trial tank Amgen's shares? And how is taxpayer money funding quantum-computing companies? Plus, will people pay $2,000 for a foldable iPhone? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why did a failed Novartis drug trial tank Amgen's shares? And how is taxpayer money funding quantum-computing companies? Plus, will people pay $2,000 for a foldable iPhone? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join David Craig, Co-Founder, President, and CEO of Sarcomatrix Therapeutics, for a masterclass on disrupting the traditional pharmaceutical development playbook. Rare neuromuscular diseases have long been underserved—not due to a lack of scientific potential, but because legacy pharma cost structures fail to scale to small patient populations. Drawing on 30 years of drug development leadership at industry giants like Amgen, Gilead, and Portola, David shares how Sarcomatrix is testing a lean, hyper-disciplined operating model to translate university research into clinical-grade therapeutics without the typical overhead waste.

Friday's edition of Morning Focus brought live coverage from Doonbeg as the village continued to welcome visitors for the Amgen Irish Open, with a strong focus on the community, local businesses, sustainability and the village's rich heritage. Alan Morrissey spoke with Adrian Kelly, Chief Fire Officer with Clare County Council, and Jenny Drysdale of Doonbeg Community Development, about the work being done by Clare County Council and the local community to promote Doonbeg and create a festive atmosphere throughout the village. They discussed the support being provided by the Council during the Irish Open, as well as the range of activities available for those who want to enjoy Doonbeg beyond the golf course. We also heard from Karen Foley, Environmental Awareness Officer with Clare County Council, about sustainability and waste management in Doonbeg this weekend. She discussed how the community is coming together to make the Fáilte Fest a greener event and the steps being taken to manage waste and promote environmental awareness. Anne Behan from McConnell Woollen Mills and Bernadette Haugh, Head of Enterprise with Clare County Council and the Local Enterprise Office Clare, joined us to discuss how local businesses are being supported and promoted during the Amgen Irish Open and Walker Cup. We also explored Doonbeg's history and heritage, with Aisling Horgan Ryan telling us about the new free Audio Heritage Trail. The award-winning Doonbeg Heritage Trail, first launched in 2022, has now been expanded to include audio, allowing visitors to explore 29 points of interest while hearing the stories, folklore and history connected to the people and places around them. Image (c) Clare FM

Four Clare businesses have the opportunity to benefit from the large numbers of visitors descending on Trump International Golf Links and Hotel Doonbeg. Action is well underway on day two, with Irish heroes Shane Lowry, Rory McIlroy and Padraig Harrington all in action this morning.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself to meet increasing global demand for affordable treatments. This initiative not only enhances their production capabilities but also aligns with the push from healthcare systems worldwide for more economical care options. The vertical integration model promises to streamline production, reduce supply chain issues, and maintain high-quality standards, reinforcing Sandoz's competitive position in the biosimilars market. Meanwhile, Amgen has achieved a noteworthy milestone with its drug Imdelltra (tarlatamab-dlle), which met its Phase 3 overall survival endpoint for extensive-stage small-cell lung cancer (SCLC) maintenance therapy. Imdelltra, a bispecific T-cell engager targeting DLL3, represents a novel approach in oncology, potentially setting a new standard of care for SCLC patients who have severely limited treatment options. The positive trial results could lead to regulatory approval, broadening access to this innovative therapy and potentially improving patient outcomes significantly. Regulatory stability is on the horizon with the FDA appointing permanent heads for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). This leadership continuity is crucial as it supports the agency's ongoing restructuring efforts aimed at enhancing efficiency and oversight. Stable leadership within these centers ensures rigorous drug evaluation processes continue, which is critical for timely approvals and has a direct impact on drug developers' strategic planning and market entry timelines. Clinical trials continue to yield varied results, showcasing the inherent uncertainties in drug development. AstraZeneca's Tozorakimab showed promise with approximately a 30% reduction in exacerbations in Phase 3 trials for chronic obstructive pulmonary disease (COPD), hinting at improved management of respiratory diseases through targeted monoclonal antibody therapies. Conversely, challenges persist as Evommune's Evo756 did not meet its Phase 2b trial expectations for atopic dermatitis, and Tyra Biosciences' Dabogratinib fell short in non-muscle invasive bladder cancer trials—highlighting the unpredictable nature of clinical research. Investment flows into biopharmaceuticals remain robust, with Encoded Therapeutics raising $275 million to advance its gene therapy program for Dravet syndrome. Similarly, Luma Group has secured $410 million for ventures focusing on ophthalmology and cellular rejuvenation technologies. Such investments reflect strong confidence in gene and cell therapies' transformative potential on patient care. On the mergers and acquisitions front, Sernova Biotherapeutics' merger with Seraxis to form Betanova Biotherapeutics exemplifies how companies are consolidating expertise to enhance R&D capabilities and expand their market reach, particularly in cell therapy solutions for diabetes management. These strategic consolidations indicate ongoing efforts to leverage synergies that could redefine therapeutic landscapes. The biopharmaceutical sector is also seeing shifts due to ongoing geopolitical tensions between the U.S. and China, pushing companies to seek investment opportunities outside China. This diversification strategy aims to mitigate geopolitical risks while continuing global innovation efforts. In obesity treatment research, partnerships like those between GemPharmaTech signal new frontiers beyond GLP-1 receptor agonists. These collaborations highlight an industry commitment to tackling global health challenges with innovative therapies that prioritize efficacy and safety. These developments collectively paint a picture of a dynamic industry marked by scientific breakthroughs, strategic investments, regulatory evolution, and significant challenges in clinical trials. As these sectors evolve, they promise exciting advancements that could profoundly redefine global healthcare paradigms. The focus remains on overcoming therapeutic barriers through sustained research efforts and innovative approaches—a testament to the industry's relentless pursuit of improving patient care outcomes worldwide.Support the show

Poor weather conditions haven't dampned spirits on the opening day of the Amgen Irish Open in Doonbeg. Large crowds were out on course early this morning for the start of Padraig Harrington's record breaking 31st consecutive Irish Open. Clare FM's Darragh O'Grady Reports

Thursday's edition of Morning Focus brought live coverage from Doonbeg as the village welcomed the Amgen Irish Open, shining a spotlight on the people, community groups and local organisations working together to showcase West Clare. Alan Morrissey spoke with Caroline O'Brien, Chairperson of Doonbeg Tidy Towns, and John O'Malley, SEO for the West Clare Municipal District with Clare County Council, about preparations throughout the village. They discussed the work being carried out by the Council, Doonbeg Tidy Towns and Doonbeg Community Development. Cathaoirleach Cllr Joe Killeen, Cllr Michael Shannon, Chair of the West Clare Municipal District, and Cllr Rita McInerney also joined us to discuss the importance of the Irish Open to West Clare. They highlighted the economic and tourism opportunities presented by such a major international sporting event. We also heard from Tommy Commerford, an original member of the Doonbeg Development Committee and one of the key figures involved in bringing the golf course to Doonbeg. Tommy shared the fascinating story of how the community approached Shannon Development, how the idea of a world-class golf course became a reality. Finally, Siobhán McNulty, Director of Service with Clare County Council's Tourism, Recreation, Libraries and Cultural Services Directorate, discussed how Visit Clare is making the most of the international attention on the county. Image (c) Clare FM

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Nando Sommerfeldt über einen mächtigen Dämpfer für Novartis, den ETF-Boom bei der DWS Group und Index-Fantasie bei SpaceX. Außerdem geht es um Novartis, Deutsche Bank, Nvidia, Fresenius, Fresenius Medical Care, Amgen, Qualcomm, Amazon, Salesforce, ServiceNow, Intuit, Apple, Bitcoin, Ether, Gold und Genius Sports. Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Ihr wollt dabei sein? Wir verlosen Tickets: Schreibt uns eine Mail an AAA@WELT.de und begründet, warum ihr unbedingt gewinnen solltet. Falls ihr euer Glück nicht dem Zufall überlassen wollt, bekommt ihr mit dem Code „AAAFRIENDS“ satte 50 Prozent Rabatt aufs Ticket – aber nur über diesen Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

Huge crowds have descended on Doonbeg for Pro Am day at the Amgen Irish Open. Home favourites Rory McIlroy and Shane Lowry attracted the biggest support on the fairways this morning, with some heavy showers passing over Doughmore Bay as they made their way around the course. There's plenty local involvement in the caddying teams, with Clare football star Mark McInerney on the bag for Padraig Harrington's group, while the rest of the local caddying team at Doonbeg were also called into action. The Make A Wish Foundation are the charity partners for the Amgen Irish Open and are located at the entrance to the Championship Village. Local schools are also having their day out to soak in the atmosphere of this historic occasion, with the likes of Clohanes, Doonbeg and Cree National schools among those represented. Former Liverpool star Robbie Fowler, along with All Ireland winners Gearoid Hegarty and Ryan O'Donoghue are among those expected to be popular on the tee later this afternoon, while former Munster star Conor Murray and ex boxer Michael Conlon will also tee it up this lunchtime.

P.M. Edition for Sept. 8. OpenAI says it's cracked the Navier-Stokes problem, one of the seven Millennium Prize Problems that are the deepest and most difficult unresolved questions in mathematics. WSJ Science of Success columnist Ben Cohen explains why labs like OpenAI are competing—and spending millions—for such breakthroughs. Plus, a dozen nations are imposing new trade restrictions on Israel over the expansion of settlements in the West Bank. And Smithsonian Secretary Lonnie Bunch III, the first African-American and the first historian to lead the institution, is stepping down after more than a year of tension with President Trump. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Amgen has its worst day in more than two decades. And quantum-computing companies rally after U.S. government picks up minority stakes. Imani Moise hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode 412 - Steve Bamford @Bamfordgolf, Paul Williams @GolfBetting and Barry O'Hanrahan @AGoodTalkGolf discuss their selections for this week's Amgen Irish Open on the DP World Tour. If you do not have a bet365 account, new customers, 18+ can access a Bet £10, get £30 in free bets offer. Use our bonus code SPORT30 when registering.  Bet £10 & Get £30 in Free Bets for new customers at bet365. Min deposit requirement. Free Bets are paid as Bet Credits and are available for use upon settlement of bets to value of qualifying deposit. Min odds, bet and payment method exclusions apply. Returns exclude Bet Credits stake. Time limits and T&Cs apply. Registration required. The bonus code SPORT30 can be used during registration, but does not change the offer amount in any way. #Ad Claim Offer Here Listeners should visit Golf Betting System for the best golf betting tips coverage. paul's amgen irish open tips We have a new set of Golf Betting System bookmaker guides, highlighting current 2026 sports accounts. boyle sports promo code betfred promo code betfred sign up offer betvictor bonus code betvictor new customer offer ladbrokes promo code ladbrokes sign up offer coral promo code coral new customer offer bet365 500 free spins bet365 new user promo unibet bonus code unibet sign up offer betmgm 40 free bets betmgm bonus code william hill promo code william hill sign up offer All offers are for new customers, 18+ Check out our new golf each way places page Steve Bamford provides pga tour betting tips across the whole of 2026 Let us talk you through the bet365 golf + bet365 each way extra + coral golf golf bet builder explained X: Steve Bamford @Bamfordgolf; Barry O'Hanrahan @AGoodTalkGolf; Paul Williams @GolfBetting Most Viewed Pages https://www.golfbettingsystem.co.uk/bet365-sign-up-offer/ https://www.golfbettingsystem.co.uk/boylesports-promo-code/ https://www.golfbettingsystem.co.uk/betfred-promo-code/ https://www.golfbettingsystem.co.uk/coral-promo-code/ https://www.golfbettingsystem.co.uk/golf-betting-a-z/ https://www.golfbettingsystem.co.uk/betmgm-promo-code/ https://www.golfbettingsystem.co.uk/coral-sign-up-offer/ https://www.golfbettingsystem.co.uk/ladbrokes-sign-up-offer/ https://www.golfbettingsystem.co.uk/ladbrokes-promo-code/ https://www.golfbettingsystem.co.uk/william-hill-promo-code-golf/ https://www.golfbettingsystem.co.uk/william-hill-sign-up-offer/ https://www.golfbettingsystem.co.uk/betfred-sign-up-offer/ https://www.golfbettingsystem.co.uk/betvictor-sign-up-offer/ https://www.golfbettingsystem.co.uk/betmgm-sign-up-offer/ https://www.golfbettingsystem.co.uk/betvictor-promo-code/ https://www.golfbettingsystem.co.uk/ladbrokes-8-places-each-way/ This podcast is for listeners of 18 and above. Please be Gambleaware, you can visit GambleAware.org for more information and of course please bet responsibly.

On this week's Out of the Rough Podcast, Nate and Jake talks all things Amgen Irish Open of the DP World Tour! Nate can be found on X @NateOoTR and Jake can be found on X @JakeOoTR. Be sure to follow Out of the Rough on all forms of social media. For more golf content, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.ootrough.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

Dan Pontefract is a renowned leadership strategist, author, and keynote speaker with over two decades of experience in senior executive roles at companies such as SAP, TELUS, and Business Objects. Since then, he has worked with organizations worldwide, including Salesforce, Amgen, Nestlé, Virgin Media O2, Autodesk, BMO, the Government of Canada, Manulife, Nutrien, and BDO, among others.As an award-winning and best-selling author, Dan has written six books: THE FUTURE OF WORK IS GREY, WORK-LIFE BLOOM, LEAD. CARE. WIN., OPEN TO THINK, THE PURPOSE EFFECT, and FLAT ARMY. His 2024, Work-Life Bloom, is the 2024 Thinkers50 Best New Management Book and the Gold Medal Winner of the Axiom Business Book Awards. He also writes for Forbes and Harvard Business Review.Dan is a renowned keynote speaker who has presented at four TED events and has delivered over 600 keynotes. He is an adjunct professor at the University of Victoria's Gustavson School of Business and has received over 25 industry, individual, and book awards.Dan's career is interwoven with corporate and academic experience, coupled with an MBA, B.Ed, and multiple industry certifications and awards. Notably, Dan is listed on the Thinkers50 Radar, HR Weekly's 100 Most Influential People in HR, PeopleHum's Top 200 Thought Leaders to Follow, and Inc. Magazine's Top 100 Leadership Speakers.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

This episode covers what matters most from ESC Congress 2026:  Heart failure (incl. cardiomyopathies) Primary and secondary prevention ACS & coronary intervention Host: Emer Joyce Guests: Davide Capodanno, Martha Gulati, John McMurray Want to watch that episode? Go to: https://esc365.escardio.org/event/2562   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Martha Gulati has declared to have potential conflicts of interest to report: Merck-Data Monitoring Committee for lipid lowering product. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. John McMurray has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Global Clinical Trial Partners Ltd., WCG Clinical Service, ARMGO Pharmaceuticals, At the Limits Ltd., Hilton Pharmaceuticals, River BioMedics, Novartis, Cytokinetics, Cardurion, Bayer AG, Chugai Pharma UK, Astra Zeneca, AnaCardio, Alnylam, Protherics Medicine Developments Ltd., DalCor Pharmaceuticals, Alkem Metabolics, Canadian Medical and Surgical Knowledge, IMEDIC Pharmaceuticals Micro Labs Ltd., Centrix Healthcare, Eris Lifesciences, Hikma Pharmacueticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceutical, Lupin Pharmaceuticals, Medscape/Heart Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, translational medicine academy, Regeneron, MCI India, Emcure Pharmaceuticals, Biohaven Pharmaceuticals, Kirkland & Ellis Int. Ltd., Tangram Therapeutics, Alphasights Ltd., APTA Therapeutics, Zoll Pharmaceuticals, MSN Lab. Ltd., Omicuris PVT Ltd. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into groundbreaking scientific advancements, crucial regulatory updates, and strategic industry movements that are shaping the future of patient care and drug development. AstraZeneca, in collaboration with Daiichi Sankyo, has achieved a significant milestone with their antibody-drug conjugate, Enhertu, combined with Roche's Perjeta. This combination therapy has recently secured European Union approval for first-line treatment of HER2-positive metastatic breast cancer. The approval highlights the transformative potential of antibody-drug conjugates in treating aggressive breast cancer subtypes. Enhertu targets HER2-positive tumors by delivering cytotoxic agents directly to the cancer cells, thereby minimizing off-target effects and enhancing efficacy. Such innovations underscore the industry's commitment to improving therapeutic outcomes for patients facing complex medical challenges. In another notable development, Novartis has entered into a substantial $3.2 billion licensing agreement with Alteogen, focusing on ALT-B4 hyaluronidase technology. This collaboration emphasizes the growing interest in subcutaneous drug formulations that offer improved patient compliance and convenience compared to traditional intravenous routes. Hyaluronidase helps disperse and absorb subcutaneously injected drugs more efficiently by degrading hyaluronic acid in tissues, thereby enhancing bioavailability and reducing injection volumes. Shifting gears to clinical trial advancements, Hutchmed's combination therapy featuring Tagrisso (osimertinib) and Orpathys (savolitinib) has achieved a Phase 3 success in first-line treatment for MET-overexpressing non-small cell lung cancer. This marks an important stride towards personalized medicine approaches that target specific genetic mutations driving tumor growth. The success of this combination therapy points to a future where targeted treatments become more prevalent in addressing complex oncogenic drivers. In the realm of strategic partnerships, Novacyt and Illumina have embarked on a five-year collaboration focusing on diagnostics and DNA sequencing technologies. This partnership aims to leverage Illumina's genomic sequencing expertise to advance precision medicine efforts in diagnostics, further highlighting the importance of collaborations in overcoming technological hurdles. Meanwhile, in gene therapy developments, NewBiologix and Synastra Biotechnology have joined forces to develop stable recombinant adeno-associated viral cell lines for Duchenne muscular dystrophy therapies. Their partnership aims to address manufacturing challenges associated with gene therapies for rare diseases, potentially accelerating treatment availability for patients in need. Despite these promising advancements, the industry is not without its challenges. Cellares recently announced significant job cuts following the loss of a contract with Bristol Myers Squibb for cell therapy production. Additionally, regulatory scrutiny remains high as evidenced by the UK Medicines and Healthcare products Regulatory Agency's suspension of Amgen's Tavneos amid concerns over trial data integrity. Such developments underscore the critical importance of maintaining rigorous data standards in drug development. Turning our attention to regulatory dynamics, the Trump administration has introduced a new drug pricing model under Medicare, providing weight loss medications at reduced prices for eligible seniors. This initiative involves major players like Eli Lilly and Novo Nordisk and aims to enhance access to obesity treatments for seniors—a move that could signify a shift towards preventive healthcare. On the clinical front, Alnylam Pharmaceuticals' next-generation gene-silencing technology shows promise for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Despite setbacks faced by AstraZeneca and Ionis Pharmaceuticals in similar trials, Alnylam's approach holds potential when used alongside standard treatments. The pharmaceutical sector also sees evolving market dynamics with reverse mergers rising sharply by 1,600% in Q3. This trend rivals traditional IPOs as companies seek alternative routes to liquidity amid fluctuating investor sentiments. Such strategic adaptations reflect the industry's resilience amidst economic uncertainties. In conclusion, these developments paint a picture of an industry dynamically adapting to technological advancements, regulatory changes, and market demands. From innovative drug delivery technologies to strategic partnerships and robust regulatory frameworks, the sector remains committed to advancing precision medicine and improving patient care globally. As these trends continue to unfold, they promise significant implications for drug development processes and therapeutic paradigms across various disease landscapes.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the dynamic landscape of the industry, highlighting significant scientific breakthroughs, strategic partnerships, and regulatory updates that are reshaping healthcare as we know it. Novartis recently announced a major milestone with its BTK inhibitor, Rhapsido, which met its Phase 3 clinical trial goals for treating relapsing multiple sclerosis. This success is particularly noteworthy as it comes without any liver safety concerns, a common challenge for this class of drugs. The development of Rhapsido marks a promising advancement in managing neurological disorders, offering new hope for patients dealing with the debilitating effects of multiple sclerosis. However, not all developments are without challenges. Novartis and Bristol Myers Squibb have halted their CAR-T trials due to safety concerns linked to autoimmune conditions like lupus and multiple sclerosis. These pauses highlight the complexities involved in developing CAR-T therapies for non-oncological applications. At the same time, Roche and Simcere Zaiming have joined forces to develop SIM0660, a T-cell engager targeting B-cell diseases. This partnership, involving an initial payment of $75 million and potential milestones up to $1.53 billion, underscores the increasing interest in antibody-based therapies. These treatments leverage the body's immune system, moving towards more targeted modalities for oncology and autoimmune diseases. Meanwhile, drug pricing reforms continue to take center stage as the White House negotiates Most Favored Nation pricing agreements with pharmaceutical giants like Alcon and Astellas Pharma. These agreements aim to make medications more affordable by aligning US drug prices with those in other developed countries. Such policy initiatives reflect growing governmental efforts to address rising healthcare costs and improve access to essential medications. Shifting focus to vaccines, GSK has embarked on a Phase 3 trial for its mRNA-based flu vaccine. This initiative highlights the broader trend of extending mRNA technology beyond COVID-19 vaccines to tackle other infectious diseases. The adaptability and rapid production capabilities of mRNA platforms could revolutionize vaccine development and enhance our response to seasonal influenza. In cardiovascular health, Amgen's Repatha has shown a 20% reduction in mortality risk during a Phase 3 trial focused on primary cardiovascular prevention. This finding reinforces the critical role of PCSK9 inhibitors in lowering cholesterol levels and preventing cardiovascular events for high-risk patients. Similarly, Alumis faced setbacks when its TYK2 inhibitor failed to meet primary endpoints in a Phase 2 study for systemic lupus erythematosus. Despite this, promising subgroup signals suggest potential paths forward. On the regulatory front, the FDA has issued warnings to Alar Pharmaceuticals regarding unapproved promotional claims for its ketamine-based product ALA-3000. Additionally, Boston Scientific has suspended sales of its Imager II angiographic catheters due to manufacturing defects causing serious injuries. Medtronic is recalling its esophageal reflux monitoring capsule over safety issues tied to numerous injuries. These regulatory actions emphasize the critical importance of compliance with safety standards in protecting patient well-being. Industry innovation is further propelled by ongoing fundraising activities supporting cutting-edge research. Companies such as PMV Pharmaceuticals are advancing precision oncology therapies targeting p53 mutations, while Rakovina Therapeutics utilizes AI-powered platforms for cancer drug discovery. These efforts underscore the sector's commitment to addressing complex diseases through technological innovation. The exploration of novel therapeutic modalities continues with Eli Lilly's acquisition of Merida Biosciences for $2.88 billion to target autoimmune diseases by selectively degrading pathogenic autoantibodies. This acquisition aligns with broader trends toward precision medicine solutions aimed at modulating immune responses. In oncology news, Akeso's success with ivonescimab in biliary tract cancer exemplifies the potential of bispecific antibodies beyond initial indications. Meanwhile, Genentech's collaboration with DualityBio aims at overcoming resistance mechanisms in antibody-drug conjugates, promising expanded treatment options for patients resistant to existing therapies. Lastly, Labcorp's introduction of a new hepatitis D test represents a proactive step toward addressing diagnostic gaps in viral infections. Early detection remains crucial for effective disease management and improved patient outcomes. These developments collectively illustrate an industry at the forefront of innovation and strategic adaptation. As companies navigate these evolving landscapes, their focus remains steadfast on improving patient care through groundbreaking therapies while overcoming regulatory hurdles—a testament to their resilience and dedication in pursuing new healthcare frontiers.Support the show

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthcare agencies reach audiences. In this week’s episode of “The Top Line,” Fierce’s Ben Adams and Zoey Becker discuss how pharma marketing is evolving across social media, creative work and agency strategy. They dig into the changing approach to HIV marketing, pharma’s experiments with platforms including Snapchat, and what a collaboration with MrBeast says about the industry’s efforts to reach new audiences. They also examine how healthcare agencies are putting AI to work, pharma’s return to the winner’s circle at Cannes and why Novo Nordisk built a maze along the River Thames in London this summer. The conversation comes as Fierce Pharma Week approaches Sept. 14-17 in Philadelphia. To learn more about the topics in this episode: YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort Inside agency view: Real Chemistry’s Frank Mazzola on audience nuance and rewarding creativity Snapchat creates ad format to support pharma disclosure needs Novo Nordisk asks public to ‘Meet Me in the Middle’ in new obesity experience installation Women’s ‘new health ecosystem’ takes shape on Reddit: report See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at the American Society of Clinical Oncology meeting that garnered widespread acclaim. Targeting one of the most challenging cancers, this advancement offers renewed hope for patients with limited treatment options and sets a potential new standard in pancreatic cancer therapy. In another promising development, Amgen and AstraZeneca have successfully completed a Phase 3 trial for their drug Tezspire in eosinophilic esophagitis. This success positions Tezspire as a formidable contender in the competitive landscape of inflammatory disease treatments, directly challenging Sanofi and Regeneron's Dupixent. The focus on biologics targeting specific inflammatory pathways underscores ongoing innovation in this area, offering enhanced treatment options for patients. On the regulatory front, the FDA has expanded its authorization for Tivicay, an HIV medication, to include newborns. This move aligns with global efforts to advance pediatric HIV treatment and address public health challenges. Additionally, Roche has secured further FDA approval for diagnostic tests linked to Jazz Pharmaceuticals' oncology drug Ziihera, emphasizing the critical role of companion diagnostics in personalized medicine. Meanwhile, strategic initiatives are also taking shape in pricing agreements. The Trump administration is preparing to announce "most favored nation" pricing agreements with mid-sized biopharma companies as part of ongoing efforts to tackle drug pricing issues. Although these arrangements could lead to lower drug prices, they may also face industry resistance due to potential impacts on revenue. Flagship Pioneering's Profound Therapeutics has partnered with the Gates Foundation in a $35 million effort to discover new drug targets for preeclampsia—a dangerous pregnancy complication. Such collaborations are vital in accelerating research and offering innovative solutions to complex health problems. Artis Biosolutions is expanding its synthetic DNA and mRNA production capabilities with a new facility in Spain. This development highlights the growing importance of genetic medicines and reflects an industry shift towards next-generation therapies like gene editing and RNA-based treatments. On a global scale, CEPI is supporting Minapharm's Ebola vaccine candidate advancement into clinical trials amid a growing outbreak. This initiative is part of a broader strategy to enhance epidemic preparedness through rapid vaccine development and deployment. Another significant move comes from McKesson's $2.25 billion acquisition of Precision Medicine Group. This acquisition aims to strengthen McKesson's oncology and biopharma segments, emphasizing precision medicine's growing role in personalized cancer treatment. In the context of geopolitical dynamics, concerns about Chinese dominance in clinical trials and supply chains have been raised by Congressman Nathaniel Moran. This highlights strategic dependencies and underscores the need for robust domestic capabilities in biopharmaceutical research and manufacturing. In clinical developments, Bausch + Lomb faced setbacks with its phase 2 trial combining dry-eye disease drugs Xiidra and Miebo but remains optimistic as it advances to phase 3 trials. Conversely, Spyre Therapeutics is deprioritizing its anti-TL1A antibody approach following underwhelming phase 2 results for rheumatoid arthritis—a testament to the rigorous validation process required before new therapies can reach patients. Akeso's success with its PD-1xVEGF bispecific antibody ivonescimab in biliary tract cancer demonstrates innovative biologics' potential to expand treatment options beyond traditional indications. In regulatory news concerning Capricor Therapeutics' Duchenne muscular dystrophy therapy, an extended FDA review period reflects careful regulatory evaluation following additional data submissions. These developments paint a picture of a dynamic landscape where scientific innovation is paralleled by regulatory challenges and strategic partnerships aimed at addressing both market demands and pressing health issues. The continued focus on personalized medicine, competitive dynamics in biologics, and global collaboration efforts underscores a transformative period for pharmaceuticals and biotech industries. As these sectors evolve, they hold the promise of delivering more effective treatments worldwide while addressing unmet medical needs across various domains.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest advancements and achievements across this dynamic industry, where innovation is reaching new heights and regulatory landscapes are continuously evolving. In a groundbreaking moment for gene therapy, Ultragenyx has secured the first FDA approval for its gene therapy product, Genglycos (DTX401), aimed at treating Glycogen Storage Disease Type Ia. This rare metabolic disorder has long posed significant challenges due to the body's inability to convert glycogen into glucose. Using an adeno-associated virus vector to deliver the therapeutic gene, Genglycos has shown significant clinical efficacy in Phase 3 studies, offering new hope for patients with limited options. This achievement underscores gene therapy's potential to transform the management of metabolic diseases and sets a precedent for future innovations in treating genetic disorders. Shifting focus to monoclonal antibodies, Regeneron has received FDA approval for Pasatru (Garetosmab), a treatment for Fibrodysplasia Ossificans Progressiva (FOP), a rare and debilitating bone disease. Pasatru targets Activin A to reduce unwanted bone formation outside the normal skeleton, marking a strategic use of monoclonal antibodies in managing rare conditions. This approval provides another therapeutic avenue for FOP patients and highlights the critical role monoclonal antibodies play in addressing complex medical challenges. On the technological front, Vitestro's Aletta has become the first FDA-approved robotic blood draw device. This innovation addresses the current shortage of phlebotomists and promises enhanced efficiency in healthcare settings. The integration of robotics into routine medical procedures exemplifies how technological advancements can optimize healthcare delivery, improving patient experiences and operational workflows. In regulatory news from the UK, NICE's endorsement of Eli Lilly's once-weekly insulin Onswik for NHS coverage marks a significant step forward in diabetes management. By facilitating access to innovative treatments with more convenient dosing regimens, this approval aims to enhance patient compliance and outcomes significantly. Business development continues to drive innovation across various therapeutic areas. Eli Lilly's collaboration with Amplitude Therapeutics on an RNA vaccine platform signifies a focused effort to harness cutting-edge technologies against infectious diseases. Similarly, Chai Discovery's partnership with Bristol Myers Squibb leverages AI and machine learning to accelerate antibody discovery, showcasing how AI is reshaping drug discovery paradigms. Funding initiatives further reveal industry trends. Kynexis's successful EUR97 million Series A raise will advance its cognitive impairment schizophrenia drug toward registrational development. Such investments underscore confidence in neuroscience therapeutics and emphasize a growing focus on addressing cognitive disorders through novel small molecules. Despite these advancements, challenges persist. Amgen's decision to terminate its collaboration with TScan Therapeutics on a Crohn's disease project due to strategic realignments highlights ongoing industry shifts. Moreover, regulatory recalls impacting product safety continue to underscore the importance of maintaining rigorous standards. In other significant developments, Novo Nordisk is exploring smaller doses of its weight management drug Wegovy through a Phase 3 trial. This study reflects an industry trend towards optimizing drug formulations for enhanced efficacy and patient compliance. On the legal front, Aurinia Pharmaceuticals reached a settlement with Teva Pharmaceuticals to delay a generic version of its lupus drug Lupkynis until late 2036. This agreement secures Aurinia's market position while providing a buffer period to maximize revenue from its patented formulation. Amid geopolitical tensions, Chinese biotech companies remain confident in navigating international markets, reflecting resilience and underscoring China's growing influence in global biotech innovation. The field also observes notable movements such as Boehringer Ingelheim's improved standing in rare disease reputation rankings and B. Braun Medical's IV solution recall due to contamination concerns—highlighting ongoing challenges in product safety and quality assurance. As we wrap up, these discussions showcase an industry rapidly evolving through scientific breakthroughs, strategic collaborations, and regulatory successes. The implications are profound: from more effective therapies for rare conditions to leveraging technological advances for streamlined R&D processes. The pharmaceutical and biotech sectors are on a promising trajectory that could redefine patient care and drug development paradigms globally. Thank you for tuning into Pharma Daily; stay informed about the latest developments shaping our industry.Support the show

A baker's dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the financings, which included money for a potential challenger to Amgen's blockbuster Tepezza and a new venture from immunology professor Georg Schett with backing from Deerfield Management, Boulevard Bio.The analysts also discuss new approaches to drug cancer's “undruggable” β-catenin pathway, and whether Capricor's latest regulatory move will give Duchenne muscular dystrophy therapy deramiocel new life at FDA.View full story: https://www.biocentury.com/article/660539#BiotechFinancing #DrugDevelopment #BetaCatenin #DuchenneMuscularDystrophy #Biopharma00:00 - Introduction02:18 - Venture Rounds12:02 - Drugging β-catenin18:12 - Capricor & FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

(0:00) About the Boardroom Governance Summit (Aug 26-27, 2026)  (0:43) Intro (2:08) About the podcast sponsor: The American College of Governance Counsel. (2:54) Start of interview.  (3:56) Origin Story of Shannon Nash (7:00) Her pivot from Law to Finance (9:15) Her operating and finance career  (12:55) Her experience in tech (subscription businesses) and current COO and CFO role at Vibrant Planet (15:50) Her first board (UserTesting) and subsequent board career (Netscout, SoFi, Lazy Dog Restaurants, Silicon Valley Community Foundation)  (22:04) Cybersecurity Meets AI (28:47) Where are the Humans? The next wave in the agentic era (31:44) Regulated Boards and Risk (36:25) Private Board Experience (VC and PE).  (41:13) About Alpha AI, focusing on AI Governance (43:53) On her podcast No Boxes, Just Verses (46:45) Her obsession with the Acquired podcast (47:41) Her mentors (49:40) Quotes that she thinks of often or lives her life by. (51:06) An unusual habit or an absurd thing that she loves. Beat Shazam show (52:15) The living person she most admires. Shannon Nash is a qualified financial expert, attorney, and CPA with over 30 years at the intersection of technology, finance, and governance. She serves as a board member in both public and private companies. You can follow Evan on social media at:X: @evanepsteinLinkedIn: https://www.linkedin.com/in/epsteinevan/ Substack: https://evanepstein.substack.com/__To support this podcast you can join as a subscriber of the Boardroom Governance Newsletter at https://evanepstein.substack.com/__Music/Soundtrack (found via Free Music Archive): Seeing The Future by Dexter Britain is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License

There is no tiger! I kept thinking about that line after this conversation with Neal Foard, founder of Storyfire (www.storyfire.net). Not because it's clever. Because it's true. SPONSORED BY: Soul of Business™ Experience Find out more at ⁠https://leader.blainebartlett.com/sobecommunity We spend so much of our lives letting the wrong story run the room. A bad meeting. A missed opportunity. A moment of embarrassment. And suddenly the nervous system acts like the house is on fire. Before founding Storyfire, Neal served as worldwide head of creative learning for Saatchi & Saatchi and spent many years as Executive Creative Director in both New York and Hong Kong. Across those roles, he witnessed firsthand how stories form the backbone of teams and organizations, from ad campaigns for global brands like Lexus and Budweiser to workshops for leaders at Amgen, Major League Baseball, and Lexus. In our conversation, Neal shared a story from early in his career that landed hard: He completely botched a presentation in front of 200 clients at the Drake Hotel in Chicago. That night, he walked into the hotel bar convinced he'd blown up his career. Instead, he met a bartender who poured him a drink and told him, in effect: There is no tiger. That story stayed with him. And I can see why. Because it names something most of us forget: Fear is real. But it is not always accurate. We can shape the story we tell ourselves. We can regulate. We can breathe. We can choose what gets to be made bigger (or smaller) than it deserves. That's not just good psychology. That's leadership. That's business. That's life. And maybe that's why this conversation resonated with me so much. Neil's whole view is built around the idea that small intentional acts of care can shift outcomes. A story can do that. A leader can do that.A message can do that. And maybe that's the point. #storytelling #leadershipdevelopment #businesspurpose #compassion #effectivecommunication #soulofbusiness #compassionatecapitalism Learn more about your ad choices. Visit megaphone.fm/adchoices

Most asthma peak week coverage focuses on kids heading back to school. But adults with asthma are just as much at risk, and often don't realize it until they're already in trouble.  Kortney and Dr. Payel Gupta are joined by allergist Dr. Ashwin Shankar to talk about why asthma peak week hits adults hard, how normalizing symptoms can quietly put you at risk, and what steps to take before the season catches up with you. What we cover in this episode about adult asthma peak week What asthma peak week is, and why fall hits so hard. The third week of September brings the highest asthma-related ER visits and hospitalizations of the year. Where fall triggers hide. Teachers and school staff face mold in buildings that sat closed all summer, outdoor workers get hit with ragweed and sudden cold mornings, and farm workers stir up mold and dust during harvest. Why even controlled asthma can slip during peak week. Trigger load stacks up fast this time of year, and a flare during peak week doesn't mean you're doing something wrong. The adult habit of normalizing symptoms. Skipping hikes, avoiding stairs, or accepting a lingering cough are signs asthma isn't controlled, not just signs of getting older. How to get ahead of peak week before it hits. Confirm your asthma action plan, track how often you're reaching for your rescue inhaler, and get your flu shot at least two weeks before September ramps up. Resources Do You Have an Asthma Action Plan? A Comprehensive Guide for Asthma Treatments & Medication 10 Ways to Stay Healthy During the September Asthma Peak Week Lifestyle Changes to Manage Asthma ________ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca and Amgen for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute for professional medical advice. Always consult with your healthcare provider for any medical concerns.

Nurse practitioner and cardiology expert Colleen Walsh-Irwin returns to NP Pulse to give us all an overview of the latest guidelines for dyslipidemia. Walsh-Irwin walks us through what the new guidelines recommend, and details how NPs can work with patients to prevent cardiovascular disease and improve LDL-C scores.    This podcast made possible by Amgen. 

What sent the Dow to a new record high? And why did chip stocks stumble despite blockbuster earnings? Plus, who's behind SpaceX's most recent rally? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What sent the Dow to a new record high? And why did chip stocks stumble despite blockbuster earnings? Plus, who's behind SpaceX's most recent rally? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week we had the privilege of hosting Leif Johan Sevland, President and CEO of the Offshore Northern Seas Foundation (ONS), for a Special Edition. Leif is a Norwegian business leader and former politician with a distinguished career spanning public service and the energy sector. Prior to joining ONS, Leif served as the Mayor of Stavanger from 2005 to 2011. The ONS 2026 Conference is fast approaching, taking place from August 24–27 in Stavanger, Norway. The conference is held biennially and attracts 70,000+ global industry leaders representing over 1,100 companies and 35+ countries. We were honored to host Leif to preview this year's conference, its major themes, and the trends shaping Norway's, Europe's and the world's energy landscape. In our conversation, Leif shared a preview of what attendees can expect at ONS 2026 and how this year's conference theme, Courage, is intended to challenge industry leaders to move beyond discussion and embrace decisive action in addressing the world's evolving energy needs. We explore Norway's unique position as both a leading oil and gas producer and an energy innovator, discussing how energy security, affordability, technological innovation, and shifting geopolitical dynamics are reshaping energy markets, investment priorities, and policy around the world. We examine Europe's evolving innovation ecosystem, the accelerating adoption of AI and its growing impact on power demand, renewed interest in nuclear energy, and the convergence of energy, defense, and industrial technologies. Leif emphasizes the importance of open dialogue, global collaboration, and developing the next generation of industry leaders, and shares how ONS brings together policymakers, operators, investors, entrepreneurs, and innovators to exchange ideas and help shape the future of energy. The Veriten team will be at ONS, participating in a few panels, and connecting with good friends and with some of our partner and portfolio companies that will also be in attendance. Mike Bradley started off the discussion by noting that two key market themes remained in place: lower oil prices and stronger equity markets. The 10-year Treasury yield remained range-bound, showing little directional movement. On the equity market front, the Dow Jones Industrial Average was up ~500 to 600 points on the day, with gains driven primarily by Amgen, Caterpillar, and Goldman Sachs. On the oil market front, downward pressure on crude prices continued, with WTI falling by approximately $1/bbl to around $75/bbl. The decline was driven largely by market optimism that the temporary pause in U.S. military strikes on Iran would remain in place. He noted, however, that oil prices appear increasingly oversold from a technical perspective, having declined roughly $10 to $15/bbl over the past one to two weeks. As a result, crude prices could rebound sharply should the current military pause end or geopolitical tensions re-escalate. He concluded by highlighting key takeaways from Saudi Aramco's 2Q earnings call, noting that management delivered a decidedly bullish message on the outlook for global oil markets. According to Aramco, oil markets are far tighter than many indicators/prices suggest. Aramco noted that global markets lost ~11mmbpd of supply because of the conflict and shipping disruptions; strategic reserve releases and inventory drawdowns have masked the true extent of the shortage; inventory data understates physical market tightness; global inventories have been heavily depleted and must now be rebuilt over several years; and it would take around 18 months and roughly 2.1mmbpd of incremental demand just to restore inventories to pre-conflict levels if conditions normalize immediately. We were fortunate to also have Veriten Venture Partner Karl Liapunov join and share his insights throughout the discussion. Karl is the founder of Starting Cold and is the U.S. Ecosystem Partner at Startuplab, where he previously served as Head of Energy & Climate Tech in Oslo.

Every September, doctors see a jump in asthma attacks and ER visits. It's called Asthma Peak Week, and it usually hits the third week of September, right when families are settling into their school routines.  Kortney and Dr. Payel Gupta are joined again by Liz Elliott, a nurse administrator in school health services for Montgomery County, Maryland, and a returning guest from our food allergy episode. This time, Liz answers the questions parents ask most about asthma at school, from what actually happens during a flare to whether their child's inhaler needs to be with them or in the health room. What we cover in this episode about Asthma Peak Week from the school nurse perspective Can my child self-carry their inhaler? The rules on self-carry, and why kindergartners and teenagers are handled differently. Does the school have stock rescue inhalers (albuterol)? What stock albuterol is, and what happens if your child's own inhaler isn't there yet. What happens if my child has a flare at school? Learn the protocol that is in place if your child experiences an asthma attack, and what happens for kids who experience their first asthma flare. Signs of asthma parents might miss that their child's asthma is not under control. Nighttime awakenings and an "asthma cough" can all be early warning signs. Closing the gap between home and school. Why the plan your provider signs has to match what's sent to school, and what to bring on day one. More resources Allergy & Asthma Network: How to Avoid the September Asthma Peak Allergy & Asthma Network: Asthma Action Plan Allergy & Asthma Network: Managing Asthma at School Allergy & Asthma Network: School Resources Listen: Ep. 135: Food Allergies in School, A School Nurse's Perspective CDC Asthma School Resources NASN Asthma CPG and Toolkit __________ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca and Amgen for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute for professional medical advice. Always consult with your healthcare provider for any medical concerns.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

SpaceX on the move in after-hours trading on the back of its first earnings report since going public. Can investors expect SpaceX to blast off, or will the aerospace giant sink even further below its IPO price?Then, major Pharma earnings from giants like Pfizer and Merck beating Wall Street estimates with Amgen and Eli Lilly on deck. Founder and CEO of Portal Innovations John Flavin lays out the best trades in the Pharma market, and his reaction to Novo Nordisk's slide after disappointing guidance. Plus, why Morgan Stanley is bearish on AMD, digging into Caterpillar earnings, and can McDonald's make a comeback? Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Cybercrime Wire, hosted by Scott Schober, provides boardroom and C-suite executives, CIOs, CSOs, CISOs, IT executives and cybersecurity professionals with a breaking news story we're following. If there's a cyberattack, hack, or data breach you should know about, then we're on it. Listen to the podcast daily and hear it every hour on WCYB. The Cybercrime Wire is brought to you Cybercrime Magazine, Page ONE for Cybersecurity at https://cybercrimemagazine.com. • For more breaking news, visit https://cybercrimewire.com

A market rally kicking off the week as major indexes trade at near all-time highs with software leading the gains. The traders break down what caused the historic trading day after weeks of mega-cap losses, plus key after-hours earnings from Palantir and Onsemi. Then, the Japanese Yen trading at near 40-year lows sparking U.S. intervention. Ben Emons of FedWatch Advisors lays out the best positioning in the Treasury market after intervention, and how to trade the volatile Yen. Plus, Airlines soaring higher, Boeing getting a double upgrade, and why it might be time to buy Amgen. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today Razib talks to Jason Scharf, a biotech investor and podcaster. A native of San Diego, Scharf is an angel investor and startup advisor focused on the intersection of biology, technology, and business, particularly within TechBio and digital health. He has leadership experience in strategy and market intelligence at major companies like Illumina and Amgen. Scharf now targets investments in the bio-innovation tech stack and care delivery transformation. Additionally, as the host of the Austin Next podcast, he is an advocate for regional innovation ecosystems. Scharf promotes the growth of the Texas Triangle as a premier global hub for biotechnology and frontier tech. Razib and Scharf discuss the growth and appeal of Austin, Texas, highlighting its booming tech scene and business environment. Scharf discusses why he moved from San Diego during the COVID-19 pandemic. They compare Austin's population growth to other major cities, noting Austin's rapid expansion from 400,000 in 1990 to over a million in 2020. They also talk about the impact of autonomous vehicles, the potential for high-speed rail, and the importance of infrastructure and talent in sustaining Austin's future growth. The conversation touches on the broader Texas Triangle and its economic significance to the American economy today and in the future. They highlight the libertarian and business-friendly environment in Texas, allowing for significant developments like Tesla's Gigafactory (the world's second-largest building), and the planned Terfab. Razib compares Austin and San Antonio, noting the former's rapid growth and the challenges it faces, such as infrastructure and housing. They also touch on the cultural and economic dynamics in Texas, emphasizing the importance of storytelling and narrative in shaping the state's future.  

In this episode of Inside Biotech, Karishma Chhugani sits down with Rene Hubert, PhD, Scientific Director of Early Career Talent and Academic Engagement at Amgen, to discuss the experiences that shaped his journey from first-generation student to biotech leader. Rene reflects on overcoming financial hardship, language barriers, self-doubt, and setbacks while staying focused on his lifelong mission to make an impact on patients through science. Rene also shares his practical five-point plan for building a successful career in biotech, emphasizing the importance of internships, embracing challenges, networking, identifying your unique strengths, and developing a personal mantra that keeps you motivated through difficult times. Whether you're a student exploring career options or an early-career scientist looking for guidance, this inspiring conversation offers valuable lessons on resilience, mentorship, and creating a meaningful career in biotechnology. Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

Hear from two experts in osteoporosis as they introduce the Osteoporosis Action Network—a volunteer coalition of osteoporosis leaders and industry partners focused on redefining the standard of care in osteoporosis, with a bold ambition of preventing 3 million fractures by 2033. Rita Roy, MD, CEO, National Spine Health Foundation will discuss the coalition's mission and vision, while Susan Bukata, MD, Professor and Chair, Department of Orthopaedics, UC San Diego, will discuss the motivation behind the creation of the coalition and share her experience with post-fracture care programs. Listeners will gain insights into action they can take to get post-fracture care programs off the ground and close care gaps. Dr. Roy and Dr. Bukata are paid consultants for Amgen. Initial support for Osteoporosis Action Network provided by Amgen.This episode is sponsored by Amgen.